They would almost certainly be forced to scale down Pulse commercialization, and probably go on life support in the hope of turning over a few clinical trials with their now put of date xcel technology.
Either that or go to regal again for a massive dilutory raise, say at 2 or 3c, and then watch regal dump it down to sub 1c.
It is by far the worse option, and people who ask for it are only venting their frustration.
If the company had done nothing differently, and the shareprice was 50c everyone would be calling craig a legend and approving the deal.
Best hope we have is the equity swap imo, nobody has presented a logical argument as to a plan B yet. Especially now that it is at a premium to the embarassing market cap of arpund $14m
Add to My Watchlist
What is My Watchlist?
